Gufic Biosciences Ltd — earnings calls

Gufic Biosciences reported Q4 FY26 revenue of around INR252 crores, its strongest quarter ever, with EBITDA margin expanding to 17.73% from 13.17% a year earlier and PAT more than doubling year-over-year. Full year FY26 revenue was INR940.50 crores versus INR820 crores in FY25, with EBITDA of INR152.9 crores and PAT of INR63.2 crores. Management attributed the quarterly improvement to the Indore facility reaching EBITDA breakeven at 30% capacity utilization, a working capital reset in the Critical Care cluster, and growth in the women's health and aesthetics platforms.